Published in J Neurosci on November 01, 1982
Tranylcypromine: new perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci (2006) 0.93
Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review. J Psychiatry Neurosci (1992) 0.91
Neurochemical and metabolic aspects of antidepressants: an overview. J Psychiatry Neurosci (2000) 0.77
Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science (1996) 16.04
Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells. Proc Natl Acad Sci U S A (1981) 6.73
Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med (1994) 6.59
Nomenclature and classification of purinoceptors. Pharmacol Rev (1994) 5.32
Homobatrachotoxin in the genus Pitohui: chemical defense in birds? Science (1992) 4.73
Forskolin: a unique diterpene activator of cyclic AMP-generating systems. J Cyclic Nucleotide Res (1981) 4.05
Cerebral glucose metabolism in adults with hyperactivity of childhood onset. N Engl J Med (1990) 3.80
Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531. Mol Psychiatry (2006) 3.73
Reduced plasma dehydroepiandrosterone concentrations in Alzheimer's disease. Lancet (1989) 3.69
Hydroxylation-induced migration: the NIH shift. Recent experiments reveal an unexpected and general result of enzymatic hydroxylation of aromatic compounds. Science (1967) 3.60
Adenosine receptors: targets for future drugs. J Med Chem (1982) 3.44
Arene oxides: a new aspect of drug metabolism. Science (1974) 3.34
Cis-1,2-dihydroxy-1,2-dihydronaphthalene: a bacterial metabolite from naphthalene. Arch Biochem Biophys (1971) 3.31
Adenosine receptors in brain membranes: binding of N6-cyclohexyl[3H]adenosine and 1,3-diethyl-8-[3H]phenylxanthine. Proc Natl Acad Sci U S A (1980) 3.20
Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. Clin Chem (1986) 2.95
Alkylxanthines: inhibition of adenosine-elicited accumulation of cyclic AMP in brain slices and of brain phosphodiesterase activity. Life Sci (1979) 2.94
Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine ("Ecstasy") in serotonin transporter-deficient mice. Mol Pharmacol (1998) 2.94
Forskolin: its biological and chemical properties. Adv Cyclic Nucleotide Protein Phosphorylation Res (1986) 2.68
Adenosine receptors and behavioral actions of methylxanthines. Proc Natl Acad Sci U S A (1981) 2.66
Adenosine receptors in the central nervous system: relationship to the central actions of methylxanthines. Life Sci (1981) 2.58
Functionalized congeners of 1,3-dialkylxanthines: preparation of analogues with high affinity for adenosine receptors. J Med Chem (1985) 2.52
Activation of adenylate cyclase by the diterpene forskolin does not require the guanine nucleotide regulatory protein. J Biol Chem (1981) 2.48
1,2-naphthalene oxide as an intermediate in the microsomal hydroxylation of naphthalene. Biochemistry (1970) 2.47
Arene oxides and the NIH shift: the metabolism, toxicity and carcinogenicity of aromatic compounds. Experientia (1972) 2.45
Transplacental passage of insulin in pregnant women with insulin-dependent diabetes mellitus. Its role in fetal macrosomia. N Engl J Med (1990) 2.40
Impaired stress-coping and fear extinction and abnormal corticolimbic morphology in serotonin transporter knock-out mice. J Neurosci (2007) 2.33
Comparison of bolus and infusion methods for receptor quantitation: application to [18F]cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab (1993) 2.28
Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. Proc Natl Acad Sci U S A (1998) 2.22
Maintenance of serotonin in the intestinal mucosa and ganglia of mice that lack the high-affinity serotonin transporter: Abnormal intestinal motility and the expression of cation transporters. J Neurosci (2001) 2.19
Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. Proc Natl Acad Sci U S A (2001) 2.19
Population and familial association between the D4 dopamine receptor gene and measures of Novelty Seeking. Nat Genet (1996) 2.18
Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. Am J Med Genet (1999) 2.16
A radioisotopic method for measuring the formation of adenosine 3',5'-cyclic monophosphate in incubated slices of brain. J Neurochem (1969) 2.13
Functionalized congeners of adenosine: preparation of analogues with high affinity for A1-adenosine receptors. J Med Chem (1985) 2.12
Serotonin transporter missense mutation associated with a complex neuropsychiatric phenotype. Mol Psychiatry (2003) 2.12
Association between the oxytocin receptor (OXTR) gene and autism: relationship to Vineland Adaptive Behavior Scales and cognition. Mol Psychiatry (2007) 2.10
Batrachotoxin: chemistry and pharmacology. Science (1971) 2.09
Subclasses of adenosine receptors in the central nervous system: interaction with caffeine and related methylxanthines. Cell Mol Neurobiol (1983) 2.04
Quality control procedure for 6-[18F]fluoro-L-DOPA: a presynaptic PET imaging ligand for brain dopamine neurons. J Nucl Med (1989) 2.04
Biochemical characterization of a filtered synaptoneurosome preparation from guinea pig cerebral cortex: cyclic adenosine 3':5'-monophosphate-generating systems, receptors, and enzymes. J Neurosci (1985) 2.02
Presynaptic dopaminergic deficits in Lesch-Nyhan disease. N Engl J Med (1996) 1.99
Organization of the human serotonin transporter gene. J Neural Transm Gen Sect (1994) 1.97
Social approach in genetically engineered mouse lines relevant to autism. Genes Brain Behav (2008) 1.94
Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. J Neurochem (1993) 1.93
Evaluation of a susceptibility gene for schizophrenia on chromosome 6p by multipoint affected sib-pair linkage analysis. Nat Genet (1995) 1.90
Toxicity of Panamanian poison frogs (Dendrobates): some biological and chemical aspects. Science (1967) 1.88
1,3-Dialkyl-8-(p-sulfophenyl)xanthines: potent water-soluble antagonists for A1- and A2-adenosine receptors. J Med Chem (1985) 1.87
Individual differences in allocation of funds in the dictator game associated with length of the arginine vasopressin 1a receptor RS3 promoter region and correlation between RS3 length and hippocampal mRNA. Genes Brain Behav (2007) 1.86
[3H]xanthine amine congener of 1,3-dipropyl-8-phenylxanthine: an antagonist radioligand for adenosine receptors. Proc Natl Acad Sci U S A (1986) 1.85
Platelet 5-HT uptake and release stopped rapidly by formaldehyde. Nature (1975) 1.84
Dopaminergic polymorphisms associated with self-report measures of human altruism: a fresh phenotype for the dopamine D4 receptor. Mol Psychiatry (2005) 1.77
Association between tridimensional personality questionnaire (TPQ) traits and three functional polymorphisms: dopamine receptor D4 (DRD4), serotonin transporter promoter region (5-HTTLPR) and catechol O-methyltransferase (COMT). Mol Psychiatry (2000) 1.74
A genetic association for cigarette smoking behavior. Health Psychol (1999) 1.69
Adenosine receptor binding: structure-activity analysis generates extremely potent xanthine antagonists. Proc Natl Acad Sci U S A (1983) 1.68
Association between the arginine vasopressin 1a receptor (AVPR1a) gene and autism in a family-based study: mediation by socialization skills. Mol Psychiatry (2006) 1.64
Alkaloids from dendrobatid frogs: structures of two omega-hydroxy congeners of 3-butyl-5-propylindolizidine and occurrence of 2,5-disubstituted pyrrolidines and a 2,6-disubstituted piperidine. J Nat Prod (1986) 1.61
Brain metabolism in teenagers with attention-deficit hyperactivity disorder. Arch Gen Psychiatry (1993) 1.60
A double blind, randomised, controlled trial of glutamine supplementation in parenteral nutrition. Gut (1999) 1.58
The role of arene oxide-oxepin systems in the metabolism of aromatic substrates. 3. Formation of 1,2-naphthalene oxide from naphthalene by liver microsomes. J Am Chem Soc (1968) 1.58
Genome-wide association study of obsessive-compulsive disorder. Mol Psychiatry (2012) 1.57
A2A adenosine receptors from rat striatum and rat pheochromocytoma PC12 cells: characterization with radioligand binding and by activation of adenylate cyclase. Mol Pharmacol (1992) 1.57
Biochemical changes during clomipramine treatment of childhood obsessive-compulsive disorder. Arch Gen Psychiatry (1987) 1.56
Perhydrohistrionicotoxin: a potential ligand for the ion conductance modulator of the acetylcholine receptor. Proc Natl Acad Sci U S A (1977) 1.55
A functionalized congener approach to adenosine receptor antagonists: amino acid conjugates of 1,3-dipropylxanthine. Mol Pharmacol (1986) 1.55
Abnormal anxiety-related behavior in serotonin transporter null mutant mice: the influence of genetic background. Genes Brain Behav (2003) 1.54
A new class of tyrosine hydroxylase inhibitors and a simple assay of inhibition in vivo. Biochem Pharmacol (1967) 1.54
Probing the adenosine receptor with adenosine and xanthine biotin conjugates. FEBS Lett (1985) 1.52
A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett (1993) 1.51
Failure to activate the left temporoparietal cortex in dyslexia. An oxygen 15 positron emission tomographic study. Arch Neurol (1992) 1.48
Binding of batrachotoxinin A 20-alpha-benzoate to a receptor site associated with sodium channels in synaptic nerve ending particles. J Biol Chem (1981) 1.48
8-(3-Chlorostyryl)caffeine (CSC) is a selective A2-adenosine antagonist in vitro and in vivo. FEBS Lett (1993) 1.47
Molecular probes for extracellular adenosine receptors. Biochem Pharmacol (1987) 1.47
Levels of batrachotoxin and lack of sensitivity to its action in poison-dart frogs (Phyllobates). Science (1980) 1.46
Reduction in the density and expression, but not G-protein coupling, of serotonin receptors (5-HT1A) in 5-HT transporter knock-out mice: gender and brain region differences. J Neurosci (2000) 1.46
Histrionicotoxins: roentgen-ray analysis of the novel allenic and acetylenie spiroalkaloids isolated from a Colombian frog, Dendrobates histrionicus. Proc Natl Acad Sci U S A (1971) 1.46
Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results. Arch Gen Psychiatry (1990) 1.46
Activation of cyclic AMP-generating systems in brain membranes and slices by the diterpene forskolin: augmentation of receptor-mediated responses. J Neurochem (1982) 1.46
4-(3-Cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone (ZK 62711): a potent inhibitor of adenosine cyclic 3',5'-monophosphate phosphodiesterases in homogenates and tissue slices from rat brain. Mol Pharmacol (1976) 1.46
Frequent loss of heterozygosity at chromosome 3p14.2-3p21 in human pancreatic islet cell tumours. Clin Endocrinol (Oxf) (1999) 1.45
Adenosine receptors. Adv Cyclic Nucleotide Protein Phosphorylation Res (1985) 1.45
Epibatidine, a potent analgetic and nicotinic agonist. Mol Pharmacol (1994) 1.44
Monooxygenase activity in Cunninghamella bainieri: evidence for a fungal system similar to liver microsomes. Arch Biochem Biophys (1973) 1.44
A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to i.v. mCPP. Biol Psychiatry (1993) 1.44
A double FDG/PET study of the effects of scopolamine in older adults. Neuropsychopharmacology (1994) 1.44
A meta-analysis of the association between DRD4 polymorphism and novelty seeking. Mol Psychiatry (2002) 1.44
Species differences in structure-activity relationships of adenosine agonists and xanthine antagonists at brain A1 adenosine receptors. FEBS Lett (1986) 1.42
Dart-poison frogs. Sci Am (1983) 1.41
What's wrong with my mouse model? Advances and strategies in animal modeling of anxiety and depression. Behav Brain Res (2007) 1.41
Structure-activity relationships for N6-substituted adenosines at a brain A1-adenosine receptor with a comparison to an A2-adenosine receptor regulating coronary blood flow. Biochem Pharmacol (1986) 1.39
Phospholipase A2 activity in Epstein-Barr virus-transformed lymphoblast cells from schizophrenic patients. Biol Psychiatry (1991) 1.38
Multiple rare SAPAP3 missense variants in trichotillomania and OCD. Mol Psychiatry (2009) 1.37
Effort and cognition in depression. Arch Gen Psychiatry (1982) 1.37
Forskolin, adenylate cyclase, and cell physiology: an overview. Adv Cyclic Nucleotide Protein Phosphorylation Res (1984) 1.35
Analogues of caffeine and theophylline: effect of structural alterations on affinity at adenosine receptors. J Med Chem (1986) 1.34
Barrel pattern formation requires serotonin uptake by thalamocortical afferents, and not vesicular monoamine release. J Neurosci (2001) 1.34
Excessive activation of serotonin (5-HT) 1B receptors disrupts the formation of sensory maps in monoamine oxidase a and 5-ht transporter knock-out mice. J Neurosci (2001) 1.33
The dextro and levorotatory isomers of N-phenylisopropyladenosine: stereospecific effects on cyclic AMP-formation and evoked synaptic responses in brain slices. Life Sci (1979) 1.32
Behavioral effects of A1- and A2-selective adenosine agonists and antagonists: evidence for synergism and antagonism. J Pharmacol Exp Ther (1991) 1.31